ClinicalTrials.gg
CompletedNCT03713632SUNRISEUpdated Oct 9, 2024Results posted

Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

A Phase 3 interventional study of Secukinumab and Placebo in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Completed at 108 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
545
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Enrollment
5th of 10
545 · median 545
Started
2019
with 2 others
Phase 3
6 of 21
1 open now
Registered
2nd of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 5th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2019, is one of 6 in phase 3, and was the 2nd registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

The purpose of this study was to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study assessed the safety and tolerability of secukinumab.

Read the detailed description

This was a multicenter, randomized, double-blind, placebo-controlled, parallel group study with two secukinumab dose regimens in patients with moderate to severe HS. The study consisted of: screening (up to 4 weeks) treatment period 1 (16 weeks, active drug or placebo) and treatment period 2 (up to 1 year all patients on active drug); there was an optional extension study (NCT04179175). Adult males and females with moderate to severe HS were included, with a diagnosis of HS greater than 1 year prior to baseline. Dosing was once every 2 weeks, or once every 4 weeks via pre-filled syringe; periodic home-dosing is included.

In Treatment Period 1, participants were randomized to secukinumab Q2W, secukinumab Q4W, placebo Q2W or placebo Q4W in 1:1:0.5:0.5 ratio. In Treatment Period 2, at the Week 16 visit participants initially randomized to placebo were switched to one of the two active dose regimens (secukinumab Q2W or Q4W), while subjects randomized to secukinumab during Treatment Period 1 continued on the same dose.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • acne inversa
  • Hidradenitis suppurativa
  • maladie de Verneuil
  • inflammatory disease
  • AIN457
  • AIN457M
  • secukinumab
  • HS
  • lumps
  • skin
  • lesions
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -Written must be obtained before any assessment is performed.
  • Male and female patients ≥ 18 years of age.
  • Diagnosis of HS ≥ 1 year prior to baseline.
  • Patients with moderate to severe HS defined as:
  • A total of at least 5 inflammatory lesions, i.e. abscesses and/or inflammatory nodules AND
  • Inflammatory lesions should affect at least 2 distinct anatomic areas
  • Patients agree to daily use of topical over-the-counter antiseptics on the areas affected by HS lesions while on study treatment.

Exclusion criteria

Exclusion Criteria:

  • Total fistulae count ≥ 20 at baseline.
  • Any other active skin disease or condition that may interfere with assessment of HS.
  • Active ongoing inflammatory diseases other than HS that require treatment with prohibited medications.
  • Use or planned use of prohibited treatment. detailed in the protocol have to be adhered to.
  • History of to any of the study drug constituents.
  • History of lymphoproliferative disease or any known or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
  • Pregnant or lactating women.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
545 participants (actual)

Study arms

  • Active comparator
    Secukinumab 1

    Secukinumab 300mg every 2 weeks

    Drug: Secukinumab

  • Active comparator
    Secukinumab 2

    Secukinumab 300mg every 4 weeks

    Drug: Secukinumab

  • Placebo comparator
    Placebo 1

    Placebo group to secukinumab 300mg every 2 weeks

    Drug: Placebo

  • Placebo comparator
    Placebo 2

    Placebo group to secukinumab 300mg every 4 weeks

    Drug: Placebo

Interventions

  • Secukinumab 300mg every 2 or every 4 weeks

  • DrugPlacebo

    Placebo 300mg every 2 or every 4 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)

    HiSCR50 at Week 16 is defined as at least a 50% decrease in Abscess and inflammatory Nodule (AN) count compared to baseline with no increase in the number of abscesses and/or in the number of draining fistulas from baseline to Week 16. The baseline is defined as the last assessment (including unscheduled visits) obtained before/on the day of the first administration of the study treatment, or on the randomization date if there had been no drug administration. This endpoint was analyzed by logistic regression.

    Time frame: 16 weeks

Secondary outcomes

  1. Percentage Change From Baseline in AN Count

    Percent change from baseline in abscesses and inflammatory nodules (AN) count. This endpoint was analyzed by analysis of covariance.

    Time frame: Baseline, 16 weeks

  2. Percentage of Participants With Hidradenitis Suppurativa (HS) Flares

    Percentage of participants who experience at least one flare over 16 weeks. A flare is defined as at least a 25% increase in abscesses and inflammatory nodules (AN) count with a minimum increase of 2 AN relative to baseline. This endpoint was analyzed by logistic regression.

    Time frame: 16 weeks

  3. Percentage of Participants Achieving NRS30

    Patients achieving Numerical Rating Scale score of 30 (NRS30) at week 16, defined as at least a 30% reduction and at least one unit reduction from baseline in the Patient's Global assessment of Skin Pain (where range 0 \[no skin pain\] to 10 \[worst skin pain\]). This endpoint was analyzed by logistic regression.

    Time frame: 16 weeks

07

Results

Posted Aug 2, 2023

Participant flow

Treatment Period 1 (Until Week 16)
Participant flow — Treatment Period 1 (Until Week 16)
MilestoneAIN457 Q2WAIN457 Q4WPlaceboPlacebo - Re-randomized to AIN457 Q2WPlacebo - Re-randomized to AIN457 Q4W
Started18118018300
Full analysis set18018018300
Completed17016916700
Not completed11111600
Withdrew: Withdrawal by subject66800
Withdrew: Adverse event14400
Withdrew: Lost to follow-up11100
Withdrew: Lack of efficacy10100
Withdrew: Technical problems10100
Withdrew: Pregnancy00100
Withdrew: Misrandomized subject10000
Treatment Period 2 (After Week 16)
Participant flow — Treatment Period 2 (After Week 16)
MilestoneAIN457 Q2WAIN457 Q4WPlaceboPlacebo - Re-randomized to AIN457 Q2WPlacebo - Re-randomized to AIN457 Q4W
Started17016908186
Completed14913306869
Not completed213601317
Withdrew: Withdrawal by subject9180912
Withdrew: Adverse event63021
Withdrew: Lack of efficacy33012
Withdrew: Lost to follow-up18010
Withdrew: Physician decision12002
Withdrew: Technical problems10000
Withdrew: Death01000
Withdrew: Pregnancy01000

Outcome measures

PrimaryPercentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)

HiSCR50 at Week 16 is defined as at least a 50% decrease in Abscess and inflammatory Nodule (AN) count compared to baseline with no increase in the number of abscesses and/or in the number of draining fistulas from baseline to Week 16. The baseline is defined as the last assessment (including unscheduled visits) obtained before/on the day of the first administration of the study treatment, or on the randomization date if there had been no drug administration. This endpoint was analyzed by logistic regression.

Time frame:
16 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)
Percentage of ParticipantsAIN457 Q2WAIN457 Q4WPlacebo
Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)42.346.131.2
Statistical analysis
  • AIN457 Q2W vs Placebo · Regression, Logistic · p = 0.0149 (one-sided p-value) · Odds ratio (or): 1.64 · 95% CI 1.05 to 2.55
  • AIN457 Q4W vs Placebo · Regression, Logistic · p = 0.0022 (one-sided p-value) · Odds ratio (or): 1.90 · 95% CI 1.22 to 2.96
SecondaryPercentage Change From Baseline in AN Count

Percent change from baseline in abscesses and inflammatory nodules (AN) count. This endpoint was analyzed by analysis of covariance.

Time frame:
Baseline, 16 weeks
Reported as:
Least squares mean · Percentage change from baseline
Percentage Change From Baseline in AN Count
Percentage change from baselineAIN457 Q2WAIN457 Q4WPlacebo
Percentage Change From Baseline in AN Count-39.3 ± 4.43-45.5 ± 4.08-22.4 ± 4.84
Statistical analysis
  • AIN457 Q2W vs Placebo · ANCOVA · p = 0.0051 (one-side p-value) · Mean difference (net): -16.33 · 95% CI -28.79 to -3.88
  • AIN457 Q4W vs Placebo · ANCOVA · p = 0.0001 (one-side p-value) · Mean difference (net): -22.94 · 95% CI -35.24 to -10.63
SecondaryPercentage of Participants With Hidradenitis Suppurativa (HS) Flares

Percentage of participants who experience at least one flare over 16 weeks. A flare is defined as at least a 25% increase in abscesses and inflammatory nodules (AN) count with a minimum increase of 2 AN relative to baseline. This endpoint was analyzed by logistic regression.

Time frame:
16 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants With Hidradenitis Suppurativa (HS) Flares
Percentage of ParticipantsAIN457 Q2WAIN457 Q4WPlacebo
Percentage of Participants With Hidradenitis Suppurativa (HS) Flares20.115.627.0
Statistical analysis
  • AIN457 Q2W vs Placebo · Regression, Logistic · p = 0.0732 (one-sided p-value) · Odds ratio (or): 0.68 · 95% CI 0.41 to 1.14
  • AIN457 Q4W vs Placebo · Regression, Logistic · p = 0.0049 (one-sided p-value) · Odds ratio (or): 0.49 · 95% CI 0.29 to 0.84
SecondaryPercentage of Participants Achieving NRS30

Patients achieving Numerical Rating Scale score of 30 (NRS30) at week 16, defined as at least a 30% reduction and at least one unit reduction from baseline in the Patient's Global assessment of Skin Pain (where range 0 \[no skin pain\] to 10 \[worst skin pain\]). This endpoint was analyzed by logistic regression.

Time frame:
16 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving NRS30
Percentage of participantsAIN457 Q2WAIN457 Q4WPlacebo
Percentage of Participants Achieving NRS3038.634.722.4
Statistical analysis
  • AIN457 Q2W vs Placebo · Regression, Logistic · p = 0.0026 (one-sided p-value) · Odds ratio (or): 2.29 · 95% CI 1.28 to 4.09
  • AIN457 Q4W vs Placebo · Regression, Logistic · p = 0.0206 (one-sided p-value) · Odds ratio (or): 1.86 · 95% CI 1.03 to 3.37

Adverse events

Collected over Adverse events (AEs) were reported from first dose of study treatment, up to approximately 52 weeks for AIN457 (up to 60 weeks for subjects who did not move to the extension study) and up to 16 weeks for placebo.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 Q2W0/180 (0%)19/180 (10.6%)123/180 (68.3%)
AIN457 Q4W1/180 (0.6%)15/180 (8.3%)125/180 (69.4%)
Placebo0/183 (0%)5/183 (2.7%)84/183 (45.9%)
Any AIN457 Q2W0/261 (0%)22/261 (8.4%)174/261 (66.7%)
Any AIN457 Q4W2/266 (0.8%)23/266 (8.6%)174/266 (65.4%)
Any AIN4572/527 (0.4%)45/527 (8.5%)348/527 (66%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventAIN457 Q2WAIN457 Q4WPlaceboAny AIN457 Q2WAny AIN457 Q4WAny AIN457
HidradenitisSkin and subcutaneous tissue disorders4/1800/1800/1835/2610/2665/527
PyrexiaGeneral disorders2/1800/1801/1832/2610/2662/527
Acute kidney injuryRenal and urinary disorders2/1800/1800/1832/2610/2662/527
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1800/1800/1830/2612/2662/527
ArrhythmiaCardiac disorders1/1800/1800/1831/2610/2661/527
Myocardial infarctionCardiac disorders0/1801/1800/1830/2611/2661/527
Colitis ulcerativeGastrointestinal disorders1/1800/1800/1831/2610/2661/527
Inflammatory bowel diseaseGastrointestinal disorders0/1801/1800/1830/2611/2661/527
Systemic inflammatory response syndromeGeneral disorders1/1800/1800/1831/2610/2661/527
Unevaluable eventGeneral disorders1/1800/1800/1831/2610/2661/527
Most frequent other events
Showing 10 of 50
Most frequent other events
EventAIN457 Q2WAIN457 Q4WPlaceboAny AIN457 Q2WAny AIN457 Q4WAny AIN457
HeadacheNervous system disorders31/18027/18016/18339/26136/26675/527
HidradenitisSkin and subcutaneous tissue disorders21/18023/18014/18326/26131/26657/527
NasopharyngitisInfections and infestations21/18018/18016/18328/26125/26653/527
DiarrhoeaGastrointestinal disorders13/18014/18013/18319/26119/26638/527
Upper respiratory tract infectionInfections and infestations13/1808/1807/18316/26111/26627/527
Back painMusculoskeletal and connective tissue disorders4/18012/1804/1837/26114/26621/527
HypertensionVascular disorders11/1806/1802/18314/2617/26621/527
COVID-19Infections and infestations10/1807/1803/18313/26114/26627/527
EczemaSkin and subcutaneous tissue disorders10/1806/1801/18311/2617/26618/527
Abdominal pain upperGastrointestinal disorders3/1809/1801/1834/26110/26614/527

Baseline characteristics

Full Analysis Set (FAS)

Age, Continuous
Age, Continuous(Years)AIN457 Q2WAIN457 Q4WPlaceboTotal
Mean37.3 ± 11.4835.5 ± 11.4136.2 ± 11.2536.3 ± 11.38
Age, Customized
Age, Customized(participants)AIN457 Q2WAIN457 Q4WPlaceboTotal
Between 18 and 65 years177178181536
>=65 years3227
Sex: Female, Male
Sex: Female, Male(Participants)AIN457 Q2WAIN457 Q4WPlaceboTotal
Female98103105306
Male827778237
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AIN457 Q2WAIN457 Q4WPlaceboTotal
White133139143415
Black or African American18191249
Asian16161951
Native Hawaiian or Other Pacific Islander1001
American Indian or Alaska native75820
Multiple4116
Not Reported1001
08

Study locations

108 sites
  • Novartis Investigative Site
    San Diego, California 92103, United States
  • Novartis Investigative Site
    Whittier, California 92677, United States
  • Novartis Investigative Site
    Coral Gables, Florida 33134, United States
  • Novartis Investigative Site
    Tampa, Florida 33609, United States
  • Novartis Investigative Site
    Sandy Springs, Georgia 30328, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46256, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02111, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63104, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63110, United States
  • Novartis Investigative Site
    Omaha, Nebraska 68144, United States
  • Novartis Investigative Site
    New York, New York 10029, United States
  • Novartis Investigative Site
    Portland, Oregon 97239, United States
  • Novartis Investigative Site
    Bellaire, Texas 77401, United States
  • Novartis Investigative Site
    Pflugerville, Texas 78660, United States
  • Novartis Investigative Site
    Norfolk, Virginia 23507, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1056ABJ, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe S2000DBS, Argentina
  • Novartis Investigative Site
    Capital Federal, C1023AAB, Argentina
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Barrie, Ontario L4M 7G1, Canada
  • Novartis Investigative Site
    Richmond Hill, Ontario L4C 9M7, Canada
  • Novartis Investigative Site
    Drummondville, Quebec J2B 5L4, Canada
  • Novartis Investigative Site
    Saint Jerome, Quebec J7Z 3B8, Canada
  • Novartis Investigative Site
    Barranquilla, Atlantico 080002, Colombia
  • Novartis Investigative Site
    Bogota, 110221, Colombia
  • Novartis Investigative Site
    Zagreb, HRV 10000, Croatia
  • Novartis Investigative Site
    Usti nad Labem, Czech Republic 400 11, Czechia
  • Novartis Investigative Site
    Jihlava, 586 33, Czechia
  • Novartis Investigative Site
    Aarhus, 8000, Denmark
  • Novartis Investigative Site
    Copenhagen NV, 2400, Denmark
  • Novartis Investigative Site
    Limoges, Haute Vienne 87000, France
  • Novartis Investigative Site
    Toulon Cedex 9, Val De Marne 83800, France
  • Novartis Investigative Site
    Antony, 92160, France
  • Novartis Investigative Site
    Martigues, 13500, France
  • Novartis Investigative Site
    Nice, 06202, France
  • Novartis Investigative Site
    Reims, 51100, France
  • Novartis Investigative Site
    Rouen Cedex, 76031, France
  • Novartis Investigative Site
    Saint Mande, 94160, France
  • Novartis Investigative Site
    Saint-Etienne, 42055, France
  • Novartis Investigative Site
    Berlin, 10789, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Dessau Rosslau, 06847, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Muenchen, 81377, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Schwerin, 19055, Germany
  • Novartis Investigative Site
    Wuerzburg, 97080, Germany
  • Novartis Investigative Site
    Thessaloniki, GR 564 03, Greece
  • Novartis Investigative Site
    Athens, 161 21, Greece
  • Novartis Investigative Site
    Guatemala City, 01010, Guatemala
  • Novartis Investigative Site
    Guatemala City, 1015, Guatemala
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Kaposvar, 7400, Hungary
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Nagpur, Maharashtra 440009, India
  • Novartis Investigative Site
    Navi Mumbai, Maharashtra 400 706, India
  • Novartis Investigative Site
    Ramat Gan, 52621, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Cona, FE 44100, Italy
  • Novartis Investigative Site
    Roma, RM 00133, Italy
  • Novartis Investigative Site
    Napoli, 80131, Italy
  • Novartis Investigative Site
    Saida, 652, Lebanon
  • Novartis Investigative Site
    Kaunas, LTU LT 50161, Lithuania
  • Novartis Investigative Site
    Vilnius, Vilniaus LT 08661, Lithuania
  • Novartis Investigative Site
    Kuala Lumpur, Wilayah Persekutuan 50586, Malaysia
  • Novartis Investigative Site
    Johor Bahru, 80100, Malaysia
  • Novartis Investigative Site
    Penang, 10990, Malaysia
  • Novartis Investigative Site
    Bergen op Zoom, 4624 VT, Netherlands
  • Novartis Investigative Site
    Makati City, 1220, Philippines
  • Novartis Investigative Site
    Lodz, 90-436, Poland
  • Novartis Investigative Site
    Rzeszow, 35 055, Poland
  • Novartis Investigative Site
    Warszawa, 04141, Poland
  • Novartis Investigative Site
    Chelyabinsk, 454048, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 191123, Russian Federation
  • Novartis Investigative Site
    Smolensk, 214031, Russian Federation
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Singapore, 308205, Singapore
  • Novartis Investigative Site
    Banska Bystrica, Slovak Republic 97401, Slovakia
  • Novartis Investigative Site
    Presov, 081 81, Slovakia
  • Novartis Investigative Site
    Pretoria, Gauteng 0001, South Africa
  • Novartis Investigative Site
    Soweto, Gauteng 2013, South Africa
  • Novartis Investigative Site
    Barcelona, Catalunya 08003, Spain
  • Novartis Investigative Site
    Manises, Valencia 46940, Spain
  • Novartis Investigative Site
    Granada, 18012, Spain
  • Novartis Investigative Site
    Las Palmas de Gran Canaria, 35010, Spain
  • Novartis Investigative Site
    Madrid, 28006, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Lausanne, 1011, Switzerland
  • Novartis Investigative Site
    Zurich, CH-8091, Switzerland
  • Novartis Investigative Site
    Istanbul, TUR 34098, Turkey
  • Novartis Investigative Site
    Altunizade, 34662, Turkey
  • Novartis Investigative Site
    Izmir, 35040, Turkey
  • Novartis Investigative Site
    Talas / Kayseri, 38039, Turkey

Showing the first 100 of 108 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Sep 2021, 30 months.

Results were first posted in Aug 2023, 1 year 10 months after primary completion. A results delay was requested in Jul 2021.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2018
First posted
Oct 22, 2018
StartActual
Feb 25, 2019
Primary completionActual
Sep 23, 2021
CompletionActual
Jul 19, 2022
Results delay requested
Jul 13, 2021
Results first posted
Aug 2, 2023
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03713632
Responsible party
Sponsor
First posted
Oct 22, 2018
Start date
Feb 25, 2019
Primary completion
Sep 23, 2021
Completion
Jul 19, 2022
Results posted
Aug 2, 2023
Last update
Oct 9, 2024

Study contacts

Study Lead Study Director
study director · Novartis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion